http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-333802-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f36edd19f4e10026e4778833f2d84a05 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate | 1997-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b3c9858628ce43d7dc88907fd40b722 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b5cac36b8b56003aface31e7c11109c |
publicationDate | 2001-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | NZ-333802-A |
titleOfInvention | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
abstract | An antisense oligonucleotide comprising at least seven to about thirty-five nucleotides and a sequence complimentary to a sequence of a mammalian ribonucleotide reductase gene, or an analogue thereof. The oligonucleotide is capable of inhibiting the proliferation of neoplastic cells. Also disclosed is a method of evaluating a compound for its ability to regulate a Ras signalling pathway by assaying for an agonist or antagonist of the interaction of R2 and Raf-1 and/or Rac-1. The method comprises providing a reaction mixture containing R2 and Raf-1 and/or Rac-1 under conditions which permit the interaction of R2 and Raf-1 and/or Rac-1, in the presence of a test compound; detecting the formation of complexes between R2 and Raf-1 and/or Rac-1 or activation of a Ras signalling pathway; and comparing to a control reaction in the absence of the test substance. Lower levels of complexes or activation in the reaction mixture indicate that the test compound interferes with the interaction of R2 and Raf-1 and/or Rac-1, and higher levels indicate that the test compound enhances the interaction of R2 and Raf-1 and/or Rac-1. |
priorityDate | 1996-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1098.